Re: "Reduction in Extraocular Muscle Cross-sectional Area and Correlation With Extraocular Motility and Diplopia Following Teprotumumab for Thyroid Eye Disease"

Ophthalmic Plast Reconstr Surg. 2023 Jul-Aug;39(4):396-397. doi: 10.1097/IOP.0000000000002454. Epub 2023 Jul 4.
No abstract available

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Diplopia / chemically induced
  • Diplopia / diagnosis
  • Graves Ophthalmopathy* / drug therapy
  • Humans
  • Oculomotor Muscles*

Substances

  • teprotumumab
  • Antibodies, Monoclonal, Humanized